文献速递癫痫

阿泽图卡纳治疗成人局灶性癫痫:X-TOLE2 3期随机临床试验

Azetukalner in Adults With Focal Seizures: The X-TOLE2 Phase 3 Randomized Clinical Trial.
PubMed 文献 · JAMA Neurol · 2026-11-09

这项3期安慰剂对照随机试验在138个中心纳入374例局灶性癫痫成人患者,评估阿泽图卡纳15 mg与25 mg每日一次治疗12周的疗效与安全性。结果显示,15 mg组和25 mg组每月癫痫发作频率中位较基线下降34.5%和53.2%,均优于安慰剂的10.4%(P < .001),药物总体耐受良好。

要点

  • 阿泽图卡纳15 mg组每月发作频率中位下降34.5%,25 mg组下降53.2%,均优于安慰剂10.4%。
  • 两组与安慰剂比较P均<.001,发作频率降幅为耐药性癫痫中报告的最大降幅之一。
  • 治疗中出现的不良事件与2b期X-TOLE试验观察结果相当,总体耐受良好。

核心结论

  • 阿泽图卡纳表现出强劲、快速且持久的癫痫发作频率下降,获益-风险特征良好,支持其作为有前景的新型抗癫痫药物。

研究设计与样本

  • 3期、安慰剂对照随机临床试验,双盲期12周(2022年11月18日至2026年2月3日),在北美、南美、欧洲和亚太地区138个中心开展。
  • 筛查607例成人,纳入并随机治疗374例(女性190例[50.8%],平均[SD]年龄40.0[12.9]岁),按1:1:1分为安慰剂组125例、阿泽图卡纳15 mg组125例、25 mg组124例。
  • 纳入标准为每月4次及以上局灶性发作且稳定使用1至3种抗癫痫药物的成人局灶性癫痫患者,数据来自2026年2月26日数据库锁定。

主要发现

  • 每月发作频率中位(IQR)较基线变化:安慰剂组-10.4%(-39.1%至8.3%),15 mg组-34.5%(-61.6%至-12.3%)(P < .001 vs 安慰剂),25 mg组-53.2%(-77.2%至-28.8%)(P < .001 vs 安慰剂)。
  • 基线每月发作中位(IQR)12.75(7.56至32.97)次,既往曾试用并停用中位(IQR)5(3至8)种抗癫痫药物,336例(89.8%)合并使用2至3种抗癫痫药物。
  • 阿泽图卡纳总体耐受良好,治疗中出现的不良事件与2b期X-TOLE试验观察结果相当。

关键数值与推荐

  • 主要疗效终点为双盲期每月(28天)局灶性发作频率较基线的中位百分比变化,阿泽图卡纳对比安慰剂。
  • 安全性通过记录治疗中出现的不良事件、临床实验室检查、生命体征和心电图变化评估。

临床怎么用

  • 原文结论认为阿泽图卡纳是值得关注的新型抗癫痫药物,具有改善临床结局的重要机会。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: Despite more than 30 approved antiseizure medications, many individuals with focal epilepsy continue to experience seizures, indicating a persistent need for novel therapies. OBJECTIVE: To determine efficacy and safety of the novel, potent KV7 channel opener azetukalner for treatment of focal seizures. DESIGN, SETTING, AND PARTICIPANTS: This phase 3, placebo-controlled randomized clinical trial of azetukalner was conducted over a 12-week double-blind period (November 18, 2022, to February 3, 2026) at 138 sites in North America, South America, Europe, and Asia Pacific. Adults with focal epilepsy experiencing 4 or more focal seizures per month despite stable treatment with 1 to 3 antiseizure medications were enrolled. Data were analyzed using a dataset derived from the database lock dated February 26, 2026. INTERVENTIONS: Participants were randomized 1:1:1 to receive placebo or 15 or 25 mg of azetukalner once daily with the evening meal for 12 weeks with no titration period. Participants completing the double-blind period could enter an open-label extension. MAIN OUTCOMES AND MEASURES: The primary efficacy end point was median percentage change from baseline in monthly (28-day) focal seizure frequency during the double-blind period for azetukalner vs placebo. Safety and tolerability were assessed by recording treatment-emergent adverse events, changes in clinical laboratory findings, vital signs, and electrocardiogram. RESULTS: Of 607 adults screened, 374 participants (190 [50.8%] female; mean [SD] age, 40.0 [12.9] years) were enrolled, randomized and treated with placebo (125 participants), 15-mg azetukalner (125 participants), or 25-mg azetukalner (124 participants). Participants had a baseline median (IQR) of 12.75 (7.56 to 32.97) seizures per month and had previously tried and stopped a median (IQR) of 5 (3 to 8) antiseizure medications. Most (336 participants [89.8%]) were receiving 2 to 3 concomitant antiseizure medications. The median (IQR) change from baseline in monthly seizure frequency was -10.4% (-39.1% to 8.3%) for the placebo group, -34.5% (-61.6% to -12.3%) for the 15-mg azetukalner group (P < .001 vs placebo), and -53.2% (-77.2% to -28.8%) for the 25-mg azetukalner group (P < .001 vs placebo). Azetukalner was generally well tolerated, and treatment-emergent adverse events were comparable to those observed in the phase 2b X-TOLE trial. CONCLUSIONS AND RELEVANCE: This randomized clinical trial found that azetukalner demonstrated robust, rapid, and durable reductions in seizure frequency with a favorable benefit-risk profile. Treatment with azetukalner resulted in one of the largest median percentage reductions in seizure frequency vs placebo reported to date in patients with drug-resistant epilepsy, supporting azetukalner as a promising novel antiseizure medication with significant opportunity to improve clinical outcomes. TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT05614063.

来源:JAMA Neurol,查看原文。版权归原作者所有。

引用

  1. French JA, LaFrance WC, Ryvlin P, et al. Azetukalner in Adults With Focal Seizures: The X-TOLE2 Phase 3 Randomized Clinical Trial. JAMA Neurol. 2026. PMID: 43002431. doi:10.1001/jamaneurol.2026.4141

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。